{"doi":"10.1136/thorax.58.1.68","title":"Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia","abstract":null,"journal":"Thorax","year":2003,"id":596268,"datarank":0.6966586348712059,"base_score":4.6443908991413725,"endowment":4.6443908991413725,"self_citation_contribution":0.6966586348712059,"citation_network_contribution":0.0,"self_endowment_contribution":0.6966586348712059,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":103,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1527024,"name":"I Horvath","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia","abstract":"BACKGROUND: Primary ciliary dyskinesia (PCD) is associated with chronic airway inflammation resulting in bronchiectasis. METHODS: The levels of exhaled nitric oxide (eNO), carbon monoxide (eCO) and nasal NO (nNO) from bronchiectatic patients with PCD (n=14) were compared with those from patients with non-PCD bronchiectasis without (n=31) and with cystic fibrosis (CF) (n=20) and from normal subjects (n=37) to assess the clinical usefulness of these measurements in discriminating between PCD and other causes of bronchiectasis. RESULTS: Exhaled NO levels were lower in patients with PCD than in patients with non-PCD non-CF bronchiectasis or healthy subjects (median (range) 2.1 (1.3-3.5) ppb v 8.7 (4.5-26.0) ppb, p<0.001; 6.7 (2.6-11.9) ppb, p<0.001, respectively) but not lower than bronchiectatic patients with CF (3.0 (1.5-7.5) ppb, p>0.05). Nasal levels of nNO were significantly lower in PCD patients than in any other subjects (PCD: 54.5 (5.0-269) ppb, non-PCD bronchiectasis without CF: 680 (310-1000) ppb, non-PCD bronchiectasis with CF: 343 (30-997) ppb, control: 663 (322-1343) ppb). In contrast, eCO levels were higher in all patient groups than in control subjects (PCD: 4.5 (3.0-24.0) ppm, p<0.01, other bronchiectasis without CF: 5.0 (3.0-15.0) ppm, p<0.001; CF: 5.3 (2.0-23.0) ppm, p<0.001 v 3.0 (0.5-5.0) ppm). Low values in both eNO and nNO readings (<2.4 ppb and <187 ppb, respectively) identified PCD patients from other bronchiectatic patients with a specificity of 98% and a positive predictive value of 92%. CONCLUSION: The simultaneous measurement of eNO and nNO is a useful screening tool for PCD.","is_dataset_classified":null,"base_score":4.6443908991413725,"endowment":4.6443908991413725,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"12511725","pmcid":"PMC1746449","openalex_id":"https://openalex.org/W2168826749","authors":[],"funders":[],"total_grants":0,"fwci":4.5262,"citation_percentile":0.9481399,"influential_citations":0,"citation_trend":[{"year":2012,"count":8},{"year":2013,"count":5},{"year":2014,"count":6},{"year":2015,"count":6},{"year":2016,"count":1},{"year":2017,"count":5},{"year":2018,"count":6},{"year":2019,"count":6},{"year":2021,"count":3},{"year":2022,"count":2},{"year":2023,"count":1}],"oa_status":"bronze","license":null,"oa_locations":[{"url":"https://thorax.bmj.com/content/thoraxjnl/58/1/68.full.pdf","host_type":"journal"},{"url":"https://thorax.bmj.com/content/thoraxjnl/58/1/68.full.pdf","host_type":"publisher"},{"url":"https://syndication.highwire.org/content/doi/10.1136/thorax.58.1.68","host_type":"publisher"},{"url":"https://doi.org/10.1136/thorax.58.1.68","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/12511725","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/1746449","host_type":"repository"}],"fields_of_study":["Cystic Fibrosis Research Advances","Chronic Obstructive Pulmonary Disease (COPD) Research","Asthma and respiratory diseases"],"mesh_terms":["Adult","Breath Tests","Bronchiectasis","Carbon Monoxide","Ciliary Motility Disorders","Female","Forced Expiratory Volume","Humans","Male","Mouth Breathing","Nitric Oxide","Nose","Sensitivity and Specificity","Vital Capacity"],"keywords":["Primary ciliary dyskinesia","Bronchiectasis","Medicine","Cystic fibrosis","Gastroenterology","Exhaled nitric oxide","Internal medicine","Respiratory disease","Expiration","Airway","Nitric oxide","Asthma","Respiratory system","Pathology","Lung","Anesthesia","Spirometry"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Reduced inequalities"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T09:27:09.243443Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}